A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (TBP-PI-HBr) and Its Major Metabolite (SPR1349) in Healthy Participants
Clinical trial NCT06727136 · COMPLETED
Trial details
- NCT number
- NCT06727136
- Sponsor
- Spero Therapeutics
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-20
- Primary completion
- 2025-04-22
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.